RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

BACKGROUND: Dabrafenib (GSK2118436) is a potent ATP-competitive inhibitor of BRAF kinase and was highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. METHODS: A Phase I trial of dabrafenib was conducted to evaluate safety and tolerability in patients with incurable...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109288/
https://ncbi.nlm.nih.gov/pubmed/22608338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(12)60398-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia